산탄 프로테오믹스 자세하게 특성화 LERLIC-MS / MS 및 글루타민 정량 아스파라긴 탈 아미드

Executive Industry Relevance

Characterizing glutamine and asparagine deamidation is critical for understanding protein stability and function in disease contexts, yet current methods lack the resolution to separate and quantify these isoforms in complex proteomes. The LERLIC-MS/MS method addresses this gap by enabling isoform-specific detection, supporting mechanistic de-risking in target validation and improving predictive confidence in preclinical models. This capability enhances translational continuity by linking molecular PTM patterns to functional outcomes across discovery stages.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of glutamine and asparagine deamidation as potential regulators of protein function in disease-relevant systems.
• Operational Value: Provides isoform-resolved data that clarifies whether observed PTMs are enzymatically driven or spontaneous, reducing mechanistic ambiguity.
• Predictive Value: Supports target confidence by distinguishing functional deamidation events from background noise in complex biological samples.

Screening & Assay Development

• Scientific Value: Generates quantitative, retention-time-resolved readouts for deamidated peptides, enabling reliable detection in screening campaigns.
• Operational Value: Delivers reproducible separation of isobaric isoforms, improving assay precision and reducing false positives in PTM-focused screens.
• Scalability: Compatible with shotgun proteomics workflows, allowing application to complex biological matrices without prior enrichment.

Translational & Preclinical Research

• Translational Biomarker Alignment: Facilitates identification of deamidation patterns that correlate with disease states or therapeutic response in preclinical models.
• Mechanistic De-risking: Stabilizes and detects the succinimide intermediate, enabling direct observation of deamidation reaction pathways for kinetic and mechanistic studies.
• Preclinical Model Relevance: Supports disease-relevant systems by characterizing PTM landscapes in tissues or cells under pathophysiological conditions.

Pipeline & Workflow Integration

The LERLIC-MS/MS method fits within the discovery continuum from early target validation through preclinical evaluation, particularly where PTM heterogeneity impacts target function or biomarker reliability.

• Discovery Biology: Supports hypothesis testing by determining whether specific glutamine or asparagine sites undergo deamidation in disease vs. control conditions.
• Screening: Enables assay-ready detection of deamidation isoforms with chromatographic separation, improving selectivity in complex lysates.
• Analytics: Provides extracted ion chromatograms and retention time shifts that allow quantitative comparison of deamidation levels across experimental conditions.
• Translational Research: Connects PTM detection to functional outcomes by linking deamidation events to changes in protein activity or stability in disease models.
• Enterprise Reuse: Represents a reusable proteomics platform applicable across multiple targets, disease areas, and sample types without reformulation.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in PTM analysis by resolving isobaric glutamine and asparagine deamidation products that conventional methods cannot distinguish.
• Operational Value: Enhances reproducibility through standardized column chemistry and sample processing that stabilizes labile intermediates like succinimide.
• Strategic Value: Improves go/no-go decisions by providing mechanistic insight into PTM-driven target instability or loss of function.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on deamidation susceptibility and functional consequence.

Implementation Considerations

• Requires expertise in proteomics sample preparation, chromatographic method development, and mass spectrometry data interpretation.
• Dependent on ultra-high pressure liquid chromatography and high-resolution mass spectrometry instrumentation capable of long-gradient separations.
• Necessitates cross-team standardization of sample handling to prevent artifactual deamidation during preparation.
• Adaptation to different model systems may require optimization of lysis and digestion conditions to preserve endogenous PTM states.
• Practical limitations include longer run times (up to 1,200 minutes) and the need for specialized column packing expertise, which may affect throughput in high-volume settings.

Biopharma FAQs